Zealand Pharma Tumbles
Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company's obesity strategy While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat on its amylin-based drug petrelintide An emerging theme in the weight loss space is the growing acknowledgement of the nee